DOCSLIB.ORG

LEUKEMIA/MDS Other Leukemias of SPECIFIED CELL TYPE C94

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LEUKEMIA/MDS Other Leukemias of SPECIFIED CELL TYPE C94 LEUKEMIA/MDS Other Leukemias of SPECIFIED CELL TYPE C94. Leukemia, C91. 0 - Acute erythroid leukemia LYMPHOID 2 - Acute megakaryoblastic leukemia 0 - Not having 3 - Mast cell leukemia achieved remission 0 - Acute lymphoblastic leukemia 4 - Acute panmyelosis with myelofibrosis 1 - In remission 1- Chronic lymphocytic leukemia of 8 - Other specified leukemias 2 - In relapse B-cell type 3 - Prolymphocytic leukemia of B-cell type 0 - Not having 6 - Myelodysplastic disease, not classified STOP 4 - Hairy cell leukemia achieved remission 5 - Adult T-cell lymphoma/leukemia 1 - In remission (HTLV-1-associated) 2 - In relapse 6 - Prolymphocytic leukemia of T-cell type Leukemia of A - Mature B-cell leukemia Burkitt-type C95. Z - Other lymphoid leukemia UNSPECIFIED 9 - Unspecified CELL TYPE 0 - Not having 0 - Acute achieved remission 1 - Chronic 1- In remission Leukemia, 9 - Unspecified C92. 2– In relapse MYELOID 0 - Acute myeloblastic leukemia Unspecified Malignant Neoplasms of 1 - Chronic myeloid leukemia, BCR/ABL- C96. positive 0 -Not having LYMPHOID, HEMATO 2 - Atypical chronic myeloid leukemia, achieved remission BCR/ABL-negative 1 - In remission POIETIC & RELATED TISSUE 3 - Myeloid sarcoma 2 - In relapse 0 - Multifocal and multisystemic (disseminated) 4 - Acute promyelocytic leukemia Langerhans-cell histiocytosis 5 - Acute myelomonocytic leukemia 2 - Malignant mast cell tumor 6 -Acute myeloid leukemia with 11q23- 4 - Sarcoma of dendritic cells (accessory cells) abnormality 5 - Multifocal and unisystemic Langerhans-cell A - Acute myeloid leukemia with histiocytosis multilineage dysplasia 6 - Unifocal Langerhans-cell histiocytosis Z - Other myeloid leukemia A - Histiocytic sarcoma 9 - Unspecified Z - Other specified 9 - Unspecified Leukemia, MONOCYTIC C93. MYELODYSPLASTIC D46. 0 - Acute monoblastic/monocytic SYNDROME (MDS) leukemia 0 - Not having achieved remission 0 - Refractory anemia without ring sideroblasts, so stated 1 - Chronic myelomonocytic leukemia 1 - Refractory anemia with ring sideroblasts 3 - Juvenile myelomonocytic leukemia 1- In remission 2– In relapse A - Refractory cytopenia with multilineage dysplasia Z - Other monocytic leukemia B - Refractory cytopenia with multilineage dysplasia and 9 - Unspecified ring sideroblasts C - Myelodysplastic syndrome with isolated del(5q) STOP chromosomal abnormality 4 - Refractory anemia, unspecified Z - Other myelodysplastic syndromes Poisoning by Adverse Effect of & Underdosing of, T45.1X 9 - Unspecified 0 - Not having achieved remission 2 - Refractory anemia ANTINEOPLASTIC & 1- 1 with excess of blasts IMMUNOSUPPRESSIVE DRUGS 2– 2 1- Poisoning by antineoplastic and Use T45.1X code for adverse effect, if applicable immunosuppressive drugs, A - initial encounter accidental (unintentional) D - subsequent encounter 5- Adverse effect of antineoplastic & S - sequela Multiple Myeloma & Malignant immunosuppressive drugs PLASMA CELL C90. NEOPLASM 0 - Multiple Myeloma 0 - Not having achieved remission 1 - Plasma cell leukemia 1 - In remission 2 - Extramedullary plasmacytoma 2 – In relapse 3 - Solitary plasmacytoma © Copyright 2015; Revised 9/24/15 HEMATOLOGY 1 B-CELL LYMPHOMA Lymphoma, Lymphoma, HODGKIN C81. OTHER C85. 0 - Nodular lymphocyte 0 - Unspecified site NON-HODGKIN predominant 1 - Head, neck, face 0 - Unspecified site 1 - Nodular sclerosis classical 2 - Intrathoracic 1 - Unspecified -B cell lymphoma 1 - Head, neck, face 2 - Mixed cellularity classical 3 - Intra-abdominal 2 - Mediastinal (thymic) large 2 - Intrathoracic 3 - Lymphocyte-depleted 4 - Axilla and upper limb B-cell 3 - Intra-abdominal classical 5 - Inguinal region and lower limb 8 - Other specified types of 4 - Axilla and upper limb 4 - Lymphocyte-rich classical 6 -Intrapelvic non-Hodgkin’s 5 - Inguinal region and lower limb 7 - Other classical 7 -Spleen 9 - Unspecified 6 -Intrapelvic 9 - Unspecified 8 - Multiple-sites 7 -Spleen 9 - Extranodal and solid organ site 8 - Multiple-sites 9 - Extranodal and solid organ site Lymphoma, Lymphomas C82. , FOLLICULAR MALIGNANT C88. 0 - Grade I 1 - Grade II 0 - Unspecified site IMMUNOPROLIFERATIVE 2 - Grade III unspecified 1 - Head, neck, face & OTHER B-CELLS 3 - Grade IIIa 2 - Intrathoracic 4 - Grade IIIb 3 - Intra-abdominal 0 - Waldenstrom macroglobulinemia 5 - Diffuse follicle center 4 - Axilla and upper limb 2 - Heavy chain disease lymphoma 5 - Inguinal region and lower limb 3 - Immunoproliferative small intestinal disease 6 - Cutaneous follicle center 6 -Intrapelvic 4 - Extranodal marginal zone B-cell lymphoma of mucosa- lymphoma 7 -Spleen associated lymphoid tissue MALT[ -lymphoma] 8 - Other types lymphoma 8 - Multiple-sites 8 - Other malignant immunoproliferative diseases 9 - Unspecified 9 - Extranodal and solid organ site 9 - Unspecified. Lymphoma, Other SPECIFIED T/NK-CELL C86. Lymphoma, 0 - Extranodal NK/T-cell lymphoma, nasal type C83. 1 - Hepatosplenic T-cell lymphoma NON-FOLLICULAR 2 - Enteropathy-type (intestinal) -T cell lymphoma 0 - Small cell B-cell Lymphoma 0 - Unspecified site 3 - Subcutaneous panniculitis-like-T-cell lymphoma 1 - Mantle cell Lymphoma 1 - Head, neck, face 4 - Blastic NK-cell lymphoma 3 - Diffuse Large -B cell 2 - Intrathoracic 5 - Angiommunoblastic -T cell lymphoma lymphoma 3 - Intra-abdominal 6 - Primary cutaneous CD-30-positive -T cell proliferations 5 - Lymphoblastic (diffuse 4 - Axilla and upper limb lymphoma) 5 - Inguinal region and lower limb 7 - Burkitt lymphoma 6 -Intrapelvic 8 - Other non-follicular 7 -Spleen Lymphoma (includes PEL/ 8 - Multiple-sites intravascular) 9 - Extranodal and solid organ site 9 - Unspecified © Copyright 2015; Revised 9/24/15 HEMATOLOGY 2 MYELOPROLIF/MGUS Neoplasms of Uncertain Behavior of POLYCYTHEMIA D45 LYMPHOID, HEMA- D47. VERA TOPOIETIC & RELATED TISSUE 0 - Histiocytic and mast cell tumors of uncertain behavior MONOCLONAL D47.2 1 - Chronic myeloproliferative disease GAMMOPATHY 2 - Monoclonal gammopathy STOP 3 - Essential (hemorrhagic) thrombocythemia 4 - Osteomyelofibrosis 9 - Unspecified Other & Unspecified Diseases of D75. Z - Other specified 1- Post-transplant lymphoproliferative BLOOD & BLOOD- neoplasms disorder (PTLD) 9 - Other specified neoplasms FORMING ORGANS For MYELOFIBROSIS, use D75.81 (MYELOFIBROSIS) 0 - Familial erythrocytosis 1 - Secondary polycythemia STOP ESSENTIAL D47.3 9 - Unspecified (HEMORRHAGIC) 8 - Other 1- MYELOFIBROSIS specified (Code first underlying disorder such as THROMBOCYTHEMIA diseases neoplasm. If applicable, code for associated of therapy-related MDS and for adverse effects blood and to identify drug) blood- 2 - Heparin induced thrombocytopenia (HIT) MYELOFIBROSIS D75.81 forming 9 - Other specified diseases of blood organs and blood-forming organs Anemia, NUTRITIONAL ANEMIAS FOLATE DEFICIENCY D52. Anemia, 0 –Dietary D50. 1 - Drug-induced IRON DEFICIENCY (Use additional code for adverse effects, 0 - Secondary to blood loss (chronic) if applicable, to identify drug) 1 - Sideropenic dysphagia 8 - Other 8 - Other iron deficiency anemias 9 - Unspecified 9 - Unspecified Anemias, Anemia, D53. D51. OTHER NUTRITIONAL VITAMIN B12 0 - Protein deficiency anemia 1 - Other megaloblastic anemias, DEFICIENCY not elsewhere classified 0 - Intrinsic factor deficiency 2 - Scorbutic anemia 1 - Selective vitamin B12 malabsorption with proteinuria 8 - Other 2 - Transcobalamin II deficiency 9 - Unspecified 3 - Other dietary Vitamin B12 deficiency 8 - Other 9 - Unspecified IRON OVERLOAD & E83.1 OTHERS 0 - Disorder of Iron Metabolism, unspecified STOP 0 - Hereditary 1 - Due to repeated red 1 - Hemochromatosis blood cell transfusions 8 - Other 9 - Unspecified © Copyright 2015; Revised 9/24/15 HEMATOLOGY Hemolytic Anemia, OTHER ANEMIAS ACQUIRED D59. 0 -Drug-induced autoimmune Anemia due to (Use additional code for adverse effects, if applicable, to D55. identify drug) ENZYME DISORDERS 1 - Other autoimmune 0 - Due to glucose-6-phosphate dehydrogenase [G6PD] deficiency 2 - Drug-induced non-autoimmune 1 - Other disorders of glutathione metabolism (Use additional code for adverse effects, if applicable, to 2 - Disorders of glycolytic enzymes identify drug) 3 - Disorders of nucleotide metabolism 3 - Hemolytic-uremic syndrome 8 - Other anemias (Use additional code to identify associated: E. coli, 9 - Unspecified Pneumoncoccal pneumonia, or Shigella dysenteriae) 4 - Other non-autoimmune 5 - Paroxysmal nocturnal hemoglobinuria (Marchiafava-Micheli) 6 - Hemoglobinuria due to hemolysis from other external causes 8 - Other acquired hemolytic anemias THALASSEMIA D56. 9 - Unspecified 0 –Alpha 1 - Beta 2 - Delta-beta 3 - Minor Other Aplastic Anemias & Other 4 - HPFH (Hereditary persistence of fetal hemoglobin) 5 - Hemoglobin E-beta D61. 8 - Other BONE MARROW 9 - Unspecified FAILURE SYNDROMES 0– Constitutional 1 - Constitutional (pure) red blood cell aplasia aplastic anemia 9 - Other constitutional aplastic anemia SICKLE CELL D57. 0 - Antineoplastic 8 - Other DISORDERS 1- Pancytopenia chemotherapy specified induced 0 - Unspecified aplastic pancytopenia 0 - Hb-SS with crisis 1 - Acute chest syndrome STOP anemias & 1 - Other drug-induced 2 - Splenic sequestration other bone pancytopenia marrow 8 - Other pancytopenia 1 - Sickle cell without crisis failure 2 - Myelophthisis 3 - Sickle-cell trait STOP syndromes 9- Other specified aplastic anemias STOP & other bone 2 - Hb-C disease 0 - Without crisis STOP 4 - Thalassemia marrow failure 8 - Other Sickle-Cell syndrome 1 - Acute chest 1 - With crisis syndrome 1 - Drug-induced aplastic anemia 2 - Splenic (If applicable, use additional code for adverse effects sequestration
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • The Hematological Complications of Alcoholism
    The Hematological Complications of Alcoholism HAROLD S. BALLARD, M.D. Alcohol has numerous adverse effects on the various types of blood cells and their functions. For example, heavy alcohol consumption can cause generalized suppression of blood cell production and the production of structurally abnormal blood cell precursors that cannot mature into functional cells. Alcoholics frequently have defective red blood cells that are destroyed prematurely, possibly resulting in anemia. Alcohol also interferes with the production and function of white blood cells, especially those that defend the body against invading bacteria. Consequently, alcoholics frequently suffer from bacterial infections. Finally, alcohol adversely affects the platelets and other components of the blood-clotting system. Heavy alcohol consumption thus may increase the drinker’s risk of suffering a stroke. KEY WORDS: adverse drug effect; AODE (alcohol and other drug effects); blood function; cell growth and differentiation; erythrocytes; leukocytes; platelets; plasma proteins; bone marrow; anemia; blood coagulation; thrombocytopenia; fibrinolysis; macrophage; monocyte; stroke; bacterial disease; literature review eople who abuse alcohol1 are at both direct and indirect. The direct in the number and function of WBC’s risk for numerous alcohol-related consequences of excessive alcohol increases the drinker’s risk of serious Pmedical complications, includ- consumption include toxic effects on infection, and impaired platelet produc- ing those affecting the blood (i.e., the the bone marrow; the blood cell pre- tion and function interfere with blood cursors; and the mature red blood blood cells as well as proteins present clotting, leading to symptoms ranging in the blood plasma) and the bone cells (RBC’s), white blood cells from a simple nosebleed to bleeding in marrow, where the blood cells are (WBC’s), and platelets.
    [Show full text]
  • Leukemoid Reaction in a Patient with Acute Lymphoblastic Leukemia Following the Second Chemotherapy
    262JCEI / Yokuş et al. Leukemoid reaction in ALL 2013; 4 (2): 262-263 Journal of Clinical and Experimental Investigations doi: 10.5799/ahinjs.01.2013.02.0280 LETTER TO EDITOR Leukemoid reaction in a patient with acute lymphoblastic leukemia following the second chemotherapy Akut lenfoblastik lösemili hastada ikinci kemoterapi sonrası gelişen lökomoid reaksiyon Osman Yokuş1, Murat Albayrak2, Aynur Albayrak3, Habip Gedik4 To the Editor, to 50.000 cells/µL. The examined peripheral blood smear appeared as similar to the chronic phase of The occurrence of persistent neutrophilic leukocy- CML (fig.2). A cytogenetic examination of Philadel- tosis above 50,000 cells/µL for reasons other than phia chromosome [t(9:22] was found to be nega- leukemia is defined as leukemoid reaction. Chronic tive, therefore, CML was excluded in the patient. myelogenous leukemia (CML) and chronic neutro- Hydroxurea was initiated once a day. Leukocytosis philic leukemia (CNL) should be excluded, and un- recovered to normal range after one week (fig.3) derlying diseases or causes should be examined, and bone marrow examination revealed remission. in differential diagnosis. The most commonly ob- Cytogenetic analysis was normal and this leukocy- served causes of leukemoid reactions are severe tosis was determined as reactive leukemoid reac- infections, intoxications, malignancies, severe hem- tion. We aimed to report this case owing to the fact orrhage, or acute hemolysis [1]. J Clin Exp Invest that leukocytosis associated with G-CSF, which is 2013; 4 (2): 262-263 used to increase the leukocyte count during neutro- Rarely, leukemoid reaction can be seen in pa- penia, has been reported previously but it occurred tients with acute leukemia subsequent to chemo- after second chemotherapy without G-CSF [4].
    [Show full text]
  • Wikipedia: the Term Leukemoid Reaction Describes an Elevated White Blood
    Correspondence: I. Potasman, MD Leukemoid Reaction: Spectrum and Prognosis of 173 Adult Patients Infectious Diseases, ABSTRACT No. Bnai Zion Med. Ctr. 47 Golomb St., Haifa 31048. 39147 Israel Potasman, MD and Moti Grupper, MD Tel. 972-48359055 Fax. 972-48359755 Bnai Zion Med. Ctr., Haifa, Israel Email: [email protected] LR- CLINICAL and LABORATORY FEATURES CHRONIC DISEASES & CONDITIONS CAUSING LR METHODS WikipediA: The term leukemoid reaction describes an elevated white blood cell count, or leukocytosis, that is a physiological response to stress or infection (as Table 1: Leukemoid Reaction: Demographics, Major Clinical, and Laboratory features, and Table 2: Chronic & possible Instigating diseases Causing Leukemoid Reaction (n=173) The BZMC is a 411 bed university hospital located in Haifa, Israel. Mortality (n=173) Disease/Drug Occurrences (%) opposed to a primary blood malignancy, such as leukemia). Contains all basic departments except for neurosurgery, cardiovascular surgery and solid-tumor oncology. The respi- Parameter N (%) Alive Dead n Age (years, mean ±S.D.) 69.4 ±19.6 63.3±21.2 79.4±11.2 Background ratory intensive care unit inhabits six patients; additional respirators are in use in the 3 departments of medicine. History of Cardiovascular 86 (49.7%) Minimal-Maximal 21-97 21-97 28-97 ABSTRACT During an average year there are 29,508 hospitalizations of adults (>18 years) with ~150,000 hospitalization-days, Median 75 69 81 disease Diabetes Mellitus 46 (26.6%) and an average occupancy of 92%. Patients were eligible throughout hospital stay, and wherever they were admit- Chronic Lung disease 29 (16.8%) ted.
    [Show full text]
  • A Phase Ib Study Evaluating Cobimetinib Plus
    Official Title: A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma NCT Number: NCT03178851 Document Date: Protocol Version 5: 26-October-2018 PROTOCOL TITLE: A PHASE IB STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH V600 ADVANCED BRAF WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI−PD-1 THERAPY AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED V600 BRAF WILD-TYPE MELANOMA PROTOCOL NUMBER: CO39721 VERSION NUMBER: 5 EUDRACT NUMBER: 2016-004402-34 IND NUMBER: 135,717 TEST PRODUCTS: Cobimetinib (RO5514041) Atezolizumab (RO5541267) MEDICAL MONITOR: M.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: 14 December 2016 DATES AMENDED: Version 2: 23 June 2017 Version 3: 19 September 2017 Version 4: 3 February 2018 Version 5: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 26-Oct-2018 10:19:14 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    [Show full text]
  • Iron Deficiency and the Anemia of Chronic Disease
    Thomas G. DeLoughery, MD MACP FAWM Professor of Medicine, Pathology, and Pediatrics Oregon Health Sciences University Portland, Oregon [email protected] IRON DEFICIENCY AND THE ANEMIA OF CHRONIC DISEASE SIGNIFICANCE Lack of iron and the anemia of chronic disease are the most common causes of anemia in the world. The majority of pre-menopausal women will have some element of iron deficiency. The first clue to many GI cancers and other diseases is iron loss. Finally, iron deficiency is one of the most treatable medical disorders of the elderly. IRON METABOLISM It is crucial to understand normal iron metabolism to understand iron deficiency and the anemia of chronic disease. Iron in food is largely in ferric form (Fe+++ ) which is reduced by stomach acid to the ferrous form (Fe++). In the jejunum two receptors on the mucosal cells absorb iron. The one for heme-iron (heme iron receptor) is very avid for heme-bound iron (absorbs 30-40%). The other receptor - divalent metal transporter (DMT1) - takes up inorganic iron but is less efficient (1-10%). Iron is exported from the enterocyte via ferroportin and is then delivered to the transferrin receptor (TfR) and then to plasma transferrin. Transferrin is the main transport molecule for iron. Transferrin can deliver iron to the marrow for the use in RBC production or to the liver for storage in ferritin. Transferrin binds to the TfR on the cell and iron is delivered either for use in hemoglobin synthesis or storage. Iron that is contained in hemoglobin in senescent red cells is recycled by binding to ferritin in the macrophage and is transferred to transferrin for recycling.
    [Show full text]
  • Management of Hepatic Burkitt Lymphoma in Children
    Gastroenterology & Hepatology International Journal ISSN: 2574-8009 Management of Hepatic Burkitt Lymphoma in Children Elhoudzi J* and Harif M Case Report Pediatric Hematology & Oncology Department, University Hospital Center, Morocco Volume 3 Issue 1 Medical school of Marrakesh, Cady Ayad University, Morocco Received Date: June 02, 2018 Published Date: June 15, 2018 *Corresponding author: Jamila Elhoudzi, Pediatric Hematology & Oncology Department, University Hospital Center, Morocco, Ibn Sina street, Ammerchich, 40000, Morocco, Tel: 00212661544256; Email: [email protected] . Abstract Hepatic Burkitt lymphoma is extremely rare in childhood and can be overlooked in differential diagnosis of liver masses. Patient: A8-year-old girl presented with a 1 month history of abdominal pain and weight loss and jaundice. Results: Physical examination revealed hepatomegaly and no palpable lymph node. Laboratory finding showed mild anemia (hemoglobin, 10,8 g/dL), elevated transaminase (ALT, 305 IU/L; ASAT,755 IU/L), elevated bilitubin (Bilirubin total, 179mg/L, Bilirubin direct, 143mg/l). Abdominal ultrasound shouwed a multiple hepatic lesions. Liver biopsy examination confirmed Burkitt's lymphoma. No metastasis was detected in the thoracic cavity, bone marrow, and spinal fluid. The patient was treated with the combination regimen of cyclophosphamide, doxorubicin, vincristine, prednisone and high dose methotrexate. Cytosine arabinoside and methotrexate were added for CNS prophylaxis by intrathecal installation. Serial follow-up ultrasound showed a marked decrease in the size of hepatic lesions but residual hilar lymph nodes at 2cm and the control showed stable size of lymph node after 28 months of chemotherapy. Conclusion: The clinical feature of primary hepaticlymphoma varies from no symptom to fulminant hepatic failure. There are no specific imaging criteria for diagnosing primary hepatic Burkitt’s lymphoma.
    [Show full text]
  • Enzymatic Defect in "X-Linked" Sideroblastic Anemia: Molecular Evidence for Erythroid 6-Aminolevulinate Synthase Deficiency PHILIP D
    Proc. Nad. Acad. Sci. USA Vol. 89, pp. 4028-4032, May 1992 Medical Sciences Enzymatic defect in "X-linked" sideroblastic anemia: Molecular evidence for erythroid 6-aminolevulinate synthase deficiency PHILIP D. COTTER*, MARTIN BAUMANNt, AND DAVID F. BISHOP*t *Division of Medical and Molecular Genetics, Mount Sinai School of Medicine, Fifth Avenue and 100th Street, New York, NY 10029; and tlI. Innere Abteilung, Krankenhaus Spandau, Lynarstrasse 12, W-1000 Berlin 20, Germany Communicated by Victor A. McKusick, January 9, 1992 ABSTRACT Recently, the human gene encoding eryth- To investigate this hypothesis, the erythroid ALAS2 cod- roid-specific -aminolevulinate synthase was localized to the ing regions were amplified and sequenced from a male chromosomal region Xp2l-Xq2l, identifying this gene as the affected with pyridoxine-responsive XLSA. In this commu- logical candidate for the enzymatic defect causing "X -linked" nication, an exonic point mutation in the ALAS2 gene that sideroblastic anemia. To investigate this hypothesis, the 11 predicted the substitution of asparagine for a highly con- exonic coding regions of the -aminolevulinate synthase gene served isoleucine is characterized as evidence that the defect were amplified and sequenced from a 30-year-old Chinese male in XLSA is the deficient activity of the erythroid form of with a pyridoxine-responsive form of X-linked sideroblastic ALAS. anemia. A single T -- A transition was found in codon 471 in a highly conserved region of exon 9, resulting in an ile -+ Asn MATERIALS AND METHODS substitution. This mutation interrupted contiguous hydropho- bic residues and was predicted to transform a region of (3-sheet Case Report.
    [Show full text]
  • Chapter 121 – Anemia, Polycythemia, and White Blood Cell Disorders Episode Overview 1
    CrackCast Show Notes – Foreign Bodies – January 2017 www.canadiem.org/crackcast Chapter 121 – Anemia, Polycythemia, and White Blood Cell Disorders Episode overview 1. Outline the important aspects of the history and physical for clinically severe and non-emergent anemia 2. List 6 causes of rapid intravascular red blood cell destruction 3. List the admission criteria for nonemergent anemia 4. Classify the anemias according to MCV 5. What is the differential diagnosis of normocytic anemia? 6. What are the 3 different types of thalassemia? 7. What is the underlying pathophysiology of sideroblastic anemia? List causes of sideroblastic anemia 8. List 3 causes of B12 deficiency) and 3 causes of folate deficiency 9. List 3 drugs that can cause aplastic anemia 10. List 4 intrinsic and 4 extrinsic causes of hemolytic anemia 11. List two RBC enzyme deficiencies. How do they typically present? 12. What is the pathophysiology of G6PD? What triggers G6PD symptoms? 13. List 5 drugs that cause hemolysis in G6PD 14. List 5 causes and 4 drugs of autoimmune hemolytic anemia 15. Describe what to look for on history and physical exam in consideration of hemolytic anemia. What are at least 6 lab tests diagnostic for hemolysis? 16. What are the laboratory differences between intravascular and extravascular hemolysis? Which types of hemolytic anemia tend to be intravascular? Which are extravascular? 17. What is the pathophysiology of sickle cell disease? 18. Which presentations of sickle cell disease are associated with a sudden decrease in hemoglobin? 19. List potential end-organ complications of sickle cell disease by system 20. Describe the management of a sickle cell pain crisis 21.
    [Show full text]
  • BHS Leucocytosis and Leucopenia Dr Caers
    Leucocytoses & leucopenia Jo Caers Dept of Clinical Hematology [email protected] Bone marrow Blood Granulopoiesis Proliferation & 5 days maturation Storage 1 day Marginisation& Circulation 1 day Tissues 1-2 days Granulopoiesis Proliferation & 5 days maturation Storage 1 day Marginisation& Circulation 1 day Tissues 1-2 days Granulopoiesis Proliferation & 5 days maturation Storage 1 day Marginisation& Circulation 1 day Tissues 1-2 days Lymphocytes Monocytes NORMAL BLOOD CELL COUNT Hemoglobin 12.0 – 15.0 g/dl (F) 13.0 – 17.0 g/dl (M) Red Blood Cells 3.9 – 5.6 x 10 6/µl (F) 4.5 – 6.5 x 10 6/µl (M) Hematocrit 36 – 48% (F) 40 – 52% (M) Mean Corpuscular Volume 80 – 95µ³ Mean Hb Concentration 27 – 34 pg Conc corp mean Hb 30 – 35 g/dl Reticulocytes 0.5 – 20 % Leucocytes 4.0 – 10.0 x 10 3/µl ¨ Neutophils 1.8 – 7.5 Lymphocytes 1.5 – 3.5 Monocytes 0.2 – 0.8 Eosinophils 0.04 – 0.45 Basophils 0.01 – 0.1 Platelets 100 – 400 x 10 3/dl Hyperleucocytosis > 10.000 WBC/mm³ Normal Cells Abnormal cells or blastic cells Infections ? Neutrophilia (> 7.500/mm³) Acute Leukemias Lymphocytosis (> 4.500/mm³) Chronic Myelomonocytic Leukemias Chronic Lymhocytic leukemia Chronic Myeloid Leukemia Non Hodgkin Lymphoma Chronic Monocytosis (> 800/mm³) … Inflammations? Eosinophilia (> 400/mm³) Basophilia (> 100/mm³) Leukoerythroblastic reaction Cytopenia with immature RBCs (normoblasts) immature WBCs (agranular neutrophils, myelocytes, metamyelocytes ) Causes BM infiltration • Solid tumor or hematological malignancy • Myelofibrosis Strong BM stimulation • Infection,
    [Show full text]
  • Blueprint Genetics Comprehensive Muscular Dystrophy / Myopathy Panel
    Comprehensive Muscular Dystrophy / Myopathy Panel Test code: NE0701 Is a 125 gene panel that includes assessment of non-coding variants. In addition, it also includes the maternally inherited mitochondrial genome. Is ideal for patients with distal myopathy or a clinical suspicion of muscular dystrophy. Includes the smaller Nemaline Myopathy Panel, LGMD and Congenital Muscular Dystrophy Panel, Emery-Dreifuss Muscular Dystrophy Panel and Collagen Type VI-Related Disorders Panel. About Comprehensive Muscular Dystrophy / Myopathy Muscular dystrophies and myopathies are a complex group of neuromuscular or musculoskeletal disorders that typically result in progressive muscle weakness. The age of onset, affected muscle groups and additional symptoms depend on the type of the disease. Limb girdle muscular dystrophy (LGMD) is a group of disorders with atrophy and weakness of proximal limb girdle muscles, typically sparing the heart and bulbar muscles. However, cardiac and respiratory impairment may be observed in certain forms of LGMD. In congenital muscular dystrophy (CMD), the onset of muscle weakness typically presents in the newborn period or early infancy. Clinical severity, age of onset, and disease progression are highly variable among the different forms of LGMD/CMD. Phenotypes overlap both within CMD subtypes and among the congenital muscular dystrophies, congenital myopathies, and LGMDs. Emery-Dreifuss muscular dystrophy (EDMD) is a condition that affects mainly skeletal muscle and heart. Usually it presents in early childhood with contractures, which restrict the movement of certain joints – most often elbows, ankles, and neck. Most patients also experience slowly progressive muscle weakness and wasting, beginning with the upper arm and lower leg muscles and progressing to shoulders and hips.
    [Show full text]
  • HEMATOLOGY CASE STUDY: a Hypochromic, Microcytic Anemia
    California Association for Medical Laboratory Technology Distance Learning Program HEMATOLOGY CASE STUDY: A Hypochromic, Microcytic Anemia Course # DL-922 by Helen Sowers, MA, CLS Lecturer (Retired) CA State University – East Bay, Hayward, CA Approved for 1.0 CE CAMLT is approved by the California Department of Public Health as a CA CLS Accrediting Agency (#21) Level of Difficulty: Basic 39656 Mission Blvd. Phone: 510-792-4441 Fremont, CA 94539-3000 FAX: 510-792-3045 Notification of Distance Learning Deadline DON’T PUT YOUR LICENSE IN JEOPARDY! This is a reminder that all the continuing education units required to renew your license/certificate must be earned no later than the expiration date printed on your license/certificate. If some of your units are made up of Distance Learning courses, please allow yourself enough time to retake the test in the event you do not pass on the first attempt. CAMLT urges you to earn your CE units early! DISTANCE LEARNING ANSWER SHEET Please circle the one best answer for each question. COURSE NAME : HEMATOLOGY CASE STUDY: A HYPOCHROMIC, MICROCYTIC ANEMIA COURSE #: DL-922 NAME ____________________________________ LIC. # ____________________ DATE ____________ SIGNATURE (REQUIRED) ___________________________________________________________________ EMAIL_______________________________________________________________________________________ ADDRESS _____________________________________________________________________________ STREET CITY STATE/ZIP 1.0 CE – FEE: $12.00 (MEMBER) | $22.00 (NON-MEMBER) PAYMENT METHOD: [ ] CHECK OR [ ] CREDIT CARD # _____________________________________ TYPE – VISA OR MC EXP. DATE ________ | SECURITY CODE: ___ - ___ - ___ 1. a b c d 2. a b c d 3. a b c d 4. a b c d 5. a b c d 6. a b c d 7. a b c d 8.
    [Show full text]